Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Theravance Biopharma's Debt-to-EBITDA or its related term are showing as below:
TBPH'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.7 Med: -1.28 Max: 0.63
Current: 0.63
During the past 13 years, the highest Debt-to-EBITDA Ratio of Theravance Biopharma was 0.63. The lowest was -2.70. And the median was -1.28.
TBPH's Debt-to-EBITDA is ranked better than 61.64% of 305
companies
in the Biotechnology industry
Industry Median: 1.24
vs TBPH: 0.63
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Theravance Biopharma Debt-to-EBITDA Related Terms
Theravance Biopharma Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Theravance Biopharma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TBPH vs ACRS, SGP, ATTO: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Theravance Biopharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theravance Biopharma Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Theravance Biopharma's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Theravance Biopharma (TBPH) has a Debt-to-EBITDA of -2.01 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Theravance Biopharma. According to the industry distribution chart, Theravance Biopharma ranks #117 out of 305 companies in the Biotechnology industry, placing it in the top 38.4%.
Is Theravance Biopharma's Debt-to-EBITDA too high?
Theravance Biopharma's current Debt-to-EBITDA is -2.01. Based on the distribution chart, Theravance Biopharma ranks #117 out of 305 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Theravance Biopharma has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Theravance Biopharma's Debt-to-EBITDA compare to ACRS and SGP?
According to the Biotechnology industry distribution chart, Theravance Biopharma ranks #117 out of 305 companies for Debt-to-EBITDA. This puts Theravance Biopharma in the upper half of its industry. The industry median Debt-to-EBITDA is 1.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.24, based on 305 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Theravance Biopharma. For the Biotechnology industry, the median Debt-to-EBITDA is 1.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theravance Biopharma's current Debt-to-EBITDA is -2.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theravance Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Theravance Biopharma (TBPH) is currently considered Fairly Valued. The stock's GF Value™ is $17.27, compared to a current price of $17.09 — trading 1% below its estimated fair value. The current Debt-to-EBITDA is -2.01. Theravance Biopharma's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Theravance Biopharma (TBPH), the current Debt-to-EBITDA is -2.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theravance Biopharma (TBPH) Overvalued in 2026?
Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued.
The current stock price of $17.09 is trading 1% below its estimated GF Value™ of $17.27.
GuruFocus considers Theravance Biopharma to be Fairly Valued.
Key valuation signals for TBPH:
Debt-to-EBITDA: -2.01
GF Value™: $17.27 vs. price of $17.09 (1% below fair value)
No single metric tells the full story. See the TBPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score
Get the complete analysis for TBPH
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TBPH has been successfully added to your 
